GlassScriptPhysician profile
Sarah E Thompson
NPI 1679840326
$2,549.62
in general payments reported to CMS, 2019-2025
33 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $691 · 2022: $676 · 2023: $332 · 2024: $375 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $233.16 | 2022-2025 | Airsupra |
| Novo Nordisk INC | $222.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $166.63 | 2021-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $160.46 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.81 | 2022-2024 | Caplyta |
| Galderma Laboratories, L.P. | $139.50 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $109.62 | 2022-2023 | Menopur |
| Alkermes, INC. | $72.96 | 2022 | |
| Axsome Therapeutics, INC. | $66.55 | 2025 | Auvelity |
| Exact Sciences Corporation | $62.13 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $53.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $49.58 | 2021-2023 | Rexulti, Abilify Maintena |
| Aimmune Therapeutics, INC. | $38.82 | 2024-2025 | Zenpep |
| Optinose US, INC. | $34.73 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $34.32 | 2021 | |
| Eisai INC. | $33.31 | 2021 | |
| Nestle Healthcare Nutrition INC. | $31.11 | 2022 | |
| Daiichi Sankyo INC. | $30.36 | 2021 | |
| Lucid Diagnostics INC. | $29.69 | 2022-2023 | |
| Seqirus USA INC | $29.22 | 2024 | Flucelvax |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.61 | 2021 | |
| Glaxosmithkline, LLC. | $27.08 | 2025 | Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $26.01 | 2021 | |
| Idorsia Pharmaceuticals US INC | $23.73 | 2022 | |
| Corcept Therapeutics | $23.40 | 2025 | Korlym |
| Corium, LLC | $22.76 | 2022 | |
| Lundbeck LLC | $22.25 | 2024 | Rexulti |
| Hologic Sales and Service, LLC | $21.21 | 2023 | Aptima, Thinprep 2000 Processor |
| Gilead Sciences, INC. | $19.72 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.20 | 2023 | Nuzyra |
| Allergan, INC. | $16.51 | 2021 | |
| Genentech USA, INC. | $9.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.